 Seena Aisner
Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 1 | 2022 | 56 | 0.800 |
Why?
| | Soft Tissue Neoplasms | 4 | 2009 | 92 | 0.630 |
Why?
| | Bone Neoplasms | 4 | 2008 | 198 | 0.550 |
Why?
| | Thymus Neoplasms | 3 | 2011 | 21 | 0.530 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 965 | 0.530 |
Why?
| | Diagnosis, Differential | 10 | 2022 | 1379 | 0.510 |
Why?
| | Lung Neoplasms | 10 | 2017 | 2216 | 0.460 |
Why?
| | Octreotide | 2 | 2010 | 26 | 0.430 |
Why?
| | Breast Neoplasms | 3 | 2022 | 1957 | 0.420 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2010 | 7 | 0.420 |
Why?
| | Liposarcoma | 3 | 2009 | 26 | 0.420 |
Why?
| | Prednisone | 2 | 2010 | 235 | 0.400 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2010 | 143 | 0.400 |
Why?
| | Lipoma | 2 | 2009 | 16 | 0.390 |
Why?
| | Translocation, Genetic | 3 | 2010 | 89 | 0.390 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2010 | 41 | 0.370 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 64 | 0.360 |
Why?
| | Receptor, ErbB-2 | 2 | 2010 | 320 | 0.360 |
Why?
| | Chondroblastoma | 2 | 2006 | 3 | 0.350 |
Why?
| | Biopsy, Fine-Needle | 4 | 2014 | 69 | 0.340 |
Why?
| | Fibula | 1 | 2008 | 40 | 0.320 |
Why?
| | ErbB Receptors | 2 | 2016 | 569 | 0.320 |
Why?
| | Nevus, Spindle Cell | 1 | 2007 | 1 | 0.310 |
Why?
| | Angiofibroma | 1 | 2007 | 5 | 0.310 |
Why?
| | Leiomyoma | 1 | 2008 | 45 | 0.310 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2006 | 11 | 0.290 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1056 | 0.290 |
Why?
| | Femoral Neoplasms | 1 | 2006 | 7 | 0.280 |
Why?
| | Tibia | 1 | 2008 | 177 | 0.280 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2017 | 895 | 0.270 |
Why?
| | Head and Neck Neoplasms | 2 | 2012 | 469 | 0.270 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 181 | 0.270 |
Why?
| | Image Enhancement | 1 | 2006 | 181 | 0.260 |
Why?
| | Cheek | 1 | 2004 | 16 | 0.260 |
Why?
| | Facial Neoplasms | 1 | 2004 | 18 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 1385 | 0.250 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2016 | 83 | 0.250 |
Why?
| | Immunohistochemistry | 10 | 2014 | 1681 | 0.240 |
Why?
| | Microtomy | 1 | 2003 | 3 | 0.230 |
Why?
| | Cytological Techniques | 1 | 2003 | 24 | 0.230 |
Why?
| | Pain | 2 | 2008 | 736 | 0.220 |
Why?
| | Middle Aged | 24 | 2019 | 27510 | 0.220 |
Why?
| | Biopsy, Needle | 1 | 2003 | 188 | 0.220 |
Why?
| | Vulvar Neoplasms | 1 | 2022 | 10 | 0.210 |
Why?
| | Subcutaneous Tissue | 1 | 2022 | 17 | 0.210 |
Why?
| | Paclitaxel | 2 | 2014 | 193 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3169 | 0.200 |
Why?
| | Breast | 1 | 2022 | 140 | 0.200 |
Why?
| | Hypothalamus | 1 | 2022 | 155 | 0.200 |
Why?
| | Chromosomes, Human, Pair 11 | 2 | 2010 | 65 | 0.180 |
Why?
| | Vulva | 2 | 2022 | 24 | 0.170 |
Why?
| | Skin Neoplasms | 1 | 2006 | 762 | 0.170 |
Why?
| | Humans | 37 | 2022 | 118251 | 0.170 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 142 | 0.170 |
Why?
| | Aged | 18 | 2019 | 19594 | 0.170 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2010 | 310 | 0.170 |
Why?
| | Female | 26 | 2022 | 61261 | 0.160 |
Why?
| | Male | 25 | 2017 | 57474 | 0.160 |
Why?
| | Thymoma | 2 | 2011 | 31 | 0.160 |
Why?
| | Selenium | 2 | 2017 | 38 | 0.150 |
Why?
| | Bevacizumab | 1 | 2017 | 123 | 0.150 |
Why?
| | Adult | 17 | 2017 | 31324 | 0.150 |
Why?
| | Urinary Bladder | 1 | 2019 | 180 | 0.150 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 66 | 0.140 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 31 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 211 | 0.140 |
Why?
| | Disease-Free Survival | 4 | 2013 | 649 | 0.140 |
Why?
| | Anilides | 1 | 2016 | 69 | 0.140 |
Why?
| | Neoplasm Staging | 4 | 2017 | 1221 | 0.140 |
Why?
| | Carcinoma | 2 | 2011 | 204 | 0.140 |
Why?
| | Sputum | 1 | 2017 | 291 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 156 | 0.130 |
Why?
| | DNA Methylation | 2 | 2017 | 501 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2013 | 1161 | 0.130 |
Why?
| | Isotretinoin | 1 | 2014 | 22 | 0.120 |
Why?
| | Angiomatosis | 1 | 2013 | 4 | 0.120 |
Why?
| | Breast Diseases | 1 | 2013 | 20 | 0.120 |
Why?
| | Polyps | 1 | 2013 | 13 | 0.120 |
Why?
| | Vulvar Diseases | 1 | 2013 | 10 | 0.120 |
Why?
| | Adenoma, Oxyphilic | 1 | 2013 | 5 | 0.120 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 2 | 0.110 |
Why?
| | Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 4 | 0.110 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2013 | 35 | 0.110 |
Why?
| | Genes, ras | 1 | 2013 | 95 | 0.110 |
Why?
| | Hyperplasia | 1 | 2013 | 170 | 0.110 |
Why?
| | Pyridines | 1 | 2016 | 436 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 225 | 0.110 |
Why?
| | Interferon-alpha | 1 | 2014 | 191 | 0.110 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2010 | 26 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 58 | 0.100 |
Why?
| | Smad Proteins | 1 | 2012 | 39 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2009 | 64 | 0.100 |
Why?
| | Genetic Association Studies | 1 | 2013 | 355 | 0.100 |
Why?
| | Pneumonectomy | 3 | 2017 | 115 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.100 |
Why?
| | Immunoenzyme Techniques | 2 | 2016 | 195 | 0.100 |
Why?
| | Carboplatin | 1 | 2011 | 140 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 808 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 610 | 0.090 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 58 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 2013 | 473 | 0.090 |
Why?
| | World Health Organization | 1 | 2010 | 106 | 0.090 |
Why?
| | Tidal Volume | 1 | 2010 | 74 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2013 | 468 | 0.090 |
Why?
| | Autophagy | 1 | 2013 | 312 | 0.090 |
Why?
| | Positive-Pressure Respiration | 1 | 2010 | 70 | 0.090 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2010 | 41 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 3 | 2008 | 2433 | 0.090 |
Why?
| | Survival Analysis | 4 | 2017 | 1262 | 0.090 |
Why?
| | Fibroma | 1 | 2009 | 20 | 0.090 |
Why?
| | Genes, p16 | 1 | 2009 | 18 | 0.090 |
Why?
| | Aged, 80 and over | 6 | 2013 | 6541 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 461 | 0.090 |
Why?
| | Cell Dedifferentiation | 1 | 2009 | 30 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2016 | 2855 | 0.080 |
Why?
| | Carcinoma, Renal Cell | 1 | 2010 | 174 | 0.080 |
Why?
| | Tissue Fixation | 2 | 2008 | 30 | 0.080 |
Why?
| | Collagen | 1 | 2009 | 433 | 0.070 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2006 | 18 | 0.070 |
Why?
| | Forkhead Box Protein O1 | 1 | 2006 | 15 | 0.070 |
Why?
| | Cytodiagnosis | 1 | 2006 | 27 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2008 | 179 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 153 | 0.070 |
Why?
| | Adenoma | 1 | 2008 | 191 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 333 | 0.070 |
Why?
| | Gene Rearrangement | 1 | 2006 | 141 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 403 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 939 | 0.070 |
Why?
| | Pain Measurement | 1 | 2008 | 468 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2057 | 0.070 |
Why?
| | Rare Diseases | 1 | 2006 | 93 | 0.070 |
Why?
| | Coccidioides | 1 | 2004 | 5 | 0.060 |
Why?
| | Coccidioidomycosis | 1 | 2004 | 7 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 536 | 0.060 |
Why?
| | Shoulder Pain | 1 | 2004 | 38 | 0.060 |
Why?
| | Salivary Gland Neoplasms | 1 | 2004 | 32 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2262 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1279 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2009 | 454 | 0.060 |
Why?
| | Mesothelioma | 1 | 2004 | 31 | 0.060 |
Why?
| | Taxoids | 1 | 2004 | 98 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1937 | 0.060 |
Why?
| | Osteosarcoma | 1 | 2004 | 70 | 0.060 |
Why?
| | Fibroblasts | 1 | 2007 | 835 | 0.060 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 180 | 0.060 |
Why?
| | Tissue Array Analysis | 2 | 2013 | 52 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2017 | 9319 | 0.050 |
Why?
| | Fibroma, Desmoplastic | 1 | 2002 | 2 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1857 | 0.050 |
Why?
| | Artifacts | 1 | 2003 | 125 | 0.050 |
Why?
| | Ribs | 1 | 2002 | 32 | 0.050 |
Why?
| | Prognosis | 3 | 2016 | 3424 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 727 | 0.050 |
Why?
| | Leukopenia | 2 | 2014 | 26 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 734 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 1967 | 0.040 |
Why?
| | Fowlpox virus | 1 | 2019 | 1 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2019 | 22 | 0.040 |
Why?
| | Paraffin Embedding | 2 | 2010 | 22 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2413 | 0.040 |
Why?
| | Phosphorylation | 2 | 2013 | 1622 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1433 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2006 | 1197 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 980 | 0.040 |
Why?
| | International Agencies | 1 | 2016 | 29 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 333 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4574 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1590 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 360 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 69 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1302 | 0.030 |
Why?
| | Adolescent | 4 | 2006 | 18364 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1787 | 0.030 |
Why?
| | Chemotherapy-Induced Febrile Neutropenia | 1 | 2014 | 1 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2014 | 15 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 2014 | 158 | 0.030 |
Why?
| | Myxoma | 1 | 2013 | 11 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2013 | 82 | 0.030 |
Why?
| | Patient Selection | 1 | 2017 | 670 | 0.030 |
Why?
| | Cohort Studies | 2 | 2014 | 5078 | 0.030 |
Why?
| | Alopecia | 1 | 2013 | 33 | 0.030 |
Why?
| | Genes, p53 | 1 | 2013 | 64 | 0.030 |
Why?
| | Chemoprevention | 1 | 2013 | 89 | 0.030 |
Why?
| | Constipation | 1 | 2013 | 76 | 0.030 |
Why?
| | Demography | 1 | 2013 | 273 | 0.030 |
Why?
| | Postoperative Period | 1 | 2013 | 307 | 0.030 |
Why?
| | Tamoxifen | 1 | 2013 | 198 | 0.030 |
Why?
| | Microscopy | 1 | 2013 | 124 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 124 | 0.030 |
Why?
| | Longevity | 1 | 2013 | 150 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1237 | 0.030 |
Why?
| | Fatigue | 1 | 2013 | 293 | 0.030 |
Why?
| | Gene Deletion | 1 | 2013 | 359 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2014 | 504 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 871 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 541 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 840 | 0.020 |
Why?
| | Cetuximab | 1 | 2011 | 99 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2491 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2016 | 807 | 0.020 |
Why?
| | Estradiol | 1 | 2013 | 473 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2010 | 117 | 0.020 |
Why?
| | Child | 2 | 2006 | 19033 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 136 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 60 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1405 | 0.020 |
Why?
| | Homeostasis | 1 | 2013 | 589 | 0.020 |
Why?
| | Karyotyping | 1 | 2009 | 102 | 0.020 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2009 | 62 | 0.020 |
Why?
| | Neoplasms, Adipose Tissue | 1 | 2009 | 1 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 394 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1683 | 0.020 |
Why?
| | Retinoblastoma Protein | 1 | 2009 | 52 | 0.020 |
Why?
| | Animals | 3 | 2019 | 33152 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 888 | 0.020 |
Why?
| | Connective Tissue Cells | 1 | 2007 | 2 | 0.020 |
Why?
| | Anesthesia | 1 | 2010 | 120 | 0.020 |
Why?
| | Fixatives | 1 | 2007 | 16 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 526 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2010 | 230 | 0.020 |
Why?
| | Formaldehyde | 1 | 2007 | 50 | 0.020 |
Why?
| | Young Adult | 2 | 2013 | 10731 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2007 | 182 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 100 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 785 | 0.020 |
Why?
| | Swine | 1 | 2010 | 719 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2010 | 605 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 163 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 298 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 665 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2659 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 2837 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2262 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2007 | 233 | 0.020 |
Why?
| | Preoperative Care | 1 | 2008 | 332 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 398 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 817 | 0.020 |
Why?
| | Oxygen | 1 | 2010 | 854 | 0.020 |
Why?
| | Phenotype | 1 | 2013 | 2937 | 0.020 |
Why?
| | Hemodynamics | 1 | 2010 | 1002 | 0.020 |
Why?
| | Itraconazole | 1 | 2004 | 7 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2014 | 12929 | 0.020 |
Why?
| | Metacarpus | 1 | 2004 | 5 | 0.020 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2004 | 6 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2004 | 31 | 0.020 |
Why?
| | Pneumonia | 1 | 2010 | 579 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1157 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2004 | 134 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 139 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 3567 | 0.010 |
Why?
| | Edema | 1 | 2004 | 124 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 379 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2004 | 227 | 0.010 |
Why?
| | Skin | 1 | 2007 | 657 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2657 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 1880 | 0.010 |
Why?
| | Radiography | 1 | 2004 | 860 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1078 | 0.010 |
Why?
| | Survival Rate | 1 | 2004 | 1716 | 0.010 |
Why?
| | Health Status | 1 | 2004 | 723 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4688 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1515 | 0.010 |
Why?
| | Lung | 1 | 2010 | 3623 | 0.010 |
Why?
| | Mice | 1 | 2013 | 15446 | 0.010 |
Why?
| | United States | 1 | 2004 | 12488 | 0.000 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|